Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15790 articles
Does the use of Acellular Dermal Matrices (ADM) in women undergoing pre-pectoral implant-based breast reconstruction increase operative success versus non-use of ADM in the same setting? A systematic review
Capsular contracture, wound dehiscence and implant rippling had significant differences.
»
09/27/24
Expression profiling of circulating lncRNA GIAT4RA, lncRNA AATBC, lncRNA Sirt1-AS, and SMARCB1 in lung cancer patients
Expression of lncRNA GIAT4RA and lncRNA AATBC significantly related to stage of lung cancer.
»
09/23/24
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
Persisting or increased Ki-67 associated with lower pCR probability.
»
09/24/24
TCTN1 Induces Fatty Acid Oxidation to Promote Melanoma Metastasis.
Prostaglandin F receptor agonist fluprostenol can block HADHA/HADHB binding.
»
09/20/24
Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
HOMA-IR significantly associated with reduced low-grade PC risk.
»
08/21/24
The Innate Immune System and TRAIL-BCL-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females.
BCL-XL inhibitor navitoclax (ABT-263) improved tumor growth control.
»
09/18/24
Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients.
Patients with combined treatment had longest mean OS.
»
08/16/24
Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value.
Serum fibronectin levels could serve as valuable prognostic biomarker.
»
06/13/24
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
Superior progression-free survival for patients having more than 1.6% CD16+ T cells.
»
09/28/24
Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis
HIPK2 inhibition weakens oncogenic KRAS activity and pancreatic tumorigenesis.
»
09/28/24
< Prev
Next >